Jeroen van de Wetering de Rooij

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study

Hendrik W. Reesink, Stefan Zeuzem, Christine J. Weegink et al. · Gastroenterology · 2006 · 396 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

Mary M. Reilly, R. Matthew Miller, MA Thomson et al. · Clinical Pharmacology & Therapeutics · 2013 · 120 citations · Full text

Medicine, Immunology, Pharmacology +16

<scp>LRRK2</scp> Inhibition by <scp>BIIB122</scp> in Healthy Participants and Patients with Parkinson's Disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Maurits F. J. M. Vissers et al. · Movement Disorders · 2023 · 115 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7

André Boonstra, Bisheng Liu, Zwier M. A. Groothuismink et al. · Antiviral Therapy · 2011 · 26 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Pharmacodynamics, pharmacokinetics and safety of <scp>GSK</scp>2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor

Gretchen Bain, Christopher D. King, Kevin M. Schaab et al. · British Journal of Clinical Pharmacology · 2012 · 19 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13